Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis.
BACKGROUND
The efficacy of several prokinetic drugs on dyspeptic symptoms and on gastric emptying rates are well-established in patients with functional dyspepsia, but formal studies comparing different prokinetic drugs are lacking.


OBJECTIVE
To compare the effects of chronic oral administration of cisapride and levosulpiride in patients with functional dyspepsia and delayed gastric emptying.


METHODS
In a double-blind crossover comparison, the effects of a 4-week administration of levosulpiride (25 mg t.d.s.) and cisapride (10 mg t.d.s.) on the gastric emptying rate and on symptoms were evaluated in 30 dyspeptic patients with functional gastroparesis. At the beginning of the study and after levosulpiride or cisapride treatment, the gastric emptying time of a standard meal was measured by 13C-octanoic acid breath test. Gastrointestinal symptom scores were also evaluated.


RESULTS
The efficacy of levosulpiride was similar to that of cisapride in significantly shortening (P < 0.001) the t1/2 of gastric emptying. No significant differences were observed between the two treatments with regards to improvements in total symptom scores. However, levosulpiride was significantly more effective (P < 0.01) than cisapride in improving the impact of symptoms on the patients' every-day activities and in improving individual symptoms such as nausea, vomiting and early postprandial satiety.


CONCLUSIONS
The efficacy of levosulpiride and cisapride in reducing gastric emptying times with no relevant side-effects is similar. The impact of symptoms on patients' everyday activities and the improvement of some symptoms such as nausea, vomiting and early satiety was more evident with levosulpiride than cisapride.
Mansi
C
C
Department of Internal Medicine, Genoa University, Italy. carlom@unige.it
Borro
P
P
Giacomini
M
M
Biagini
R
R
Mele
M R
MR
Pandolfo
N
N
Savarino
V
V
D000203:Activities of Daily Living; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000494:pharmacology* / Q000627:therapeutic use; D020117:Cisapride / Q000494:pharmacology* / Q000627:therapeutic use; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004415:Dyspepsia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D005765:Gastrointestinal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018589:Gastroparesis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012527:Satiation; D013469:Sulpiride / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000897:Anti-Ulcer Agents; D005765:Gastrointestinal Agents; D013469:Sulpiride; C078143:levosulpiride; D020117:Cisapride